Delving into the Latest Updates on OxyPharma AB with Synapse

概览

关联

2

项与 OxyPharma AB 相关的临床试验

NCT00525213

/ Completed临床2期

A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate

The primary objective of this study is to evaluate the efficacy (ACR20) of Rob 803 administered orally once daily for 12 weeks in combination with a stable dose of methotrexate in subjects with moderate or severe active RA.

开始日期2007-10-01

申办/合作机构

OxyPharma AB

EUCTR2006-004834-33-BE

/ Not yet recruitingN/A

A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Added to Stable Methotrexate in Patients with Moderate or Severe Active Rheumatoid Arthritis - Robust

开始日期2007-08-25

申办/合作机构

OxyPharma AB

100 项与 OxyPharma AB 相关的临床结果

登录后查看更多信息

0 项与 OxyPharma AB 相关的专利（医药）

登录后查看更多信息

100 项与 OxyPharma AB 相关的药物交易

登录后查看更多信息

100 项与 OxyPharma AB 相关的转化医学

登录后查看更多信息